Reilly, a veteran of the diagnostic and pharmaceutical industries, is being brought in to help Agile prepare for the potential commercialization of its lead product candidate Twirla -- a low-dose prescription contraceptive delivered through the skin via the company’s proprietary patch. The company said on Thursday that he will start on August 5.
“We remain focused on seeking approval of Twirla and building a robust women’s health company,” said Agile CEO Al Altomari.” We are committed to making the investments and assembling the team we need to achieve those goals.”
The Princeton, New Jersey-based company has completed its Phase 3 clinical trials of Twirla and is pursuing regulatory approval in the US after resubmitting a New Drug Application with the Food and Drug Administration for Twirla in May.
The FDA has assigned a Prescription Drug User Fee Act action date of November 16, 2019 for the completion of its review of Twirla.
In its statement, Agile said Reilly has had significant experience with commercial companies in the pharmaceutical and diagnostics sectors.
Most recently, from 2017 to 2019, he served as chief financial and operations officer of Invisible Sentinel Inc, a Philadelphia-based diagnostics company that was sold to BioMeriux, a French biotechnology company, where he contributed to the initial commercial growth of the company.
From 2009 to 2017, Reilly was the chief financial officer of NeoStrata Company Inc, a Princeton-based global leader in dermocosmetics, which was sold to Johnson & Johnson Consumer Inc in 2017, where he oversaw several important initiatives to restructure the company and return it to financial growth.
From 2005 to 2008, he served as the chief financial officer, and prior to that role, as controller of Barrier Therapeutics Inc, a dermatology-focused specialty pharmaceutical company, which was sold to Steifel Laboratories Inc in 2008. And Reilly, a certified public accountant, was the corporate controller at the Medicines Company (NASDAQ:MDCO) from 2002 to 2005.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham